- Home
- HTO vs KLRA Comparison
HTO vs KLRA Comparison
Compare HTO & KLRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTO | KLRA |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.4B |
| IPO Year | 1994 | 2026 |
Fundamental Metrics
Financial Performance| Metric | HTO | KLRA |
|---|---|---|
| Price | $64.29 | $14.84 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $62.00 | N/A |
| AVG Volume (30 Days) | 288.1K | ★ 719.9K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | ★ 3.05% | N/A |
| EPS Growth | ★ 1.74 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $800,590,000.00 | N/A |
| Revenue This Year | $10.26 | N/A |
| Revenue Next Year | $7.06 | N/A |
| P/E Ratio | $132.27 | ★ N/A |
| Revenue Growth | ★ 6.97 | N/A |
| 52 Week Low | $43.75 | $15.15 |
| 52 Week High | $67.09 | $23.82 |
Technical Indicators
Market Signals| Indicator | HTO | KLRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.05 | 36.75 |
| Support Level | $55.58 | N/A |
| Resistance Level | $64.56 | $19.02 |
| Average True Range (ATR) | 1.18 | 1.27 |
| MACD | 0.04 | -0.12 |
| Stochastic Oscillator | 69.61 | 4.65 |
Price Performance
Historical ComparisonAbout HTO H2O America
H2O America is a national investor-owned network of local water and wastewater utilities united by one purpose: delivering clean, high-quality water to the communities it calls home. Across approximately 407,000 water and wastewater service connections, the company invests in critical infrastructure to strengthen the water supply for generations to come. Its single reportable segment provides water utility and utility-related services to its customers.
About KLRA Kailera Therapeutics Inc. Common Stock
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.